GMTX vs. ALDX, TSVT, QURE, AKBA, PRLD, PYXS, RANI, ELYM, GTHX, and OVID
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Aldeyra Therapeutics (ALDX), 2seventy bio (TSVT), uniQure (QURE), Akebia Therapeutics (AKBA), Prelude Therapeutics (PRLD), Pyxis Oncology (PYXS), Rani Therapeutics (RANI), Eliem Therapeutics (ELYM), G1 Therapeutics (GTHX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical preparations" industry.
Gemini Therapeutics (NASDAQ:GMTX) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Gemini Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aldeyra Therapeutics had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 1.32 beat Aldeyra Therapeutics' score of 0.37 indicating that Gemini Therapeutics is being referred to more favorably in the media.
Aldeyra Therapeutics has a consensus price target of $9.33, indicating a potential upside of 150.22%. Given Aldeyra Therapeutics' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Gemini Therapeutics.
Aldeyra Therapeutics received 461 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 69.26% of users gave Aldeyra Therapeutics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Aldeyra Therapeutics' return on equity of -24.69% beat Gemini Therapeutics' return on equity.
Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Aldeyra Therapeutics beats Gemini Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Gemini Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
